Article Title:

Correlation of Computed Tomography and Positron Emission Tomographty in Patients With Metastatis Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria.

(Click the name of the journal article to download the full text pdf)

Author:

Haesun Choi, MD
Director of Body MRI
Radiology/Diagnostic Imaging
University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Publication
Issue Date:

Journal of Clinical Oncology
May 1, 2007

Moderator:

Jonathan C. Trent, MD, PhD
Assistant Professor of Medicine
Sarcoma Medical Oncology
The University of Texas MD
Anderson Cancer Center
Houston, Texas

Learning Objectives:

After taking part in this activity, participants should be able to:

• Compare the changes on computed tomography (CT) for patients with metastatic gastrointestinal stromal tumors (GISTs) after treatment with imatinib with the changes in glucose metabolism on [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET)
• Evaluate the CT response criteria for predicting time to tumor progression following imatinib treatment in patients with metastatic GISTs
• Review existing clinical trial data relating to the use of the current international tumor response criteria, Response Evaluation Criteria in Solid Tumors (RECIST), for evaluating the initial tumor response to imatinib in patients with metastatic GISTs
  

Faculty Disclosures:

Haesun Choi, MD, has received contracted research from GE Healthcare.

Jonathan C, Trent, MD, PhD, reports no such relationships.

The NCME staff reports no financial relationships to disclose.